Sarepta Therapeutics said early Tuesday that a patient had died after receiving its gene therapy Elevidys, which treats the ...

Opens in a new tab or window A young person with Duchenne muscular dystrophy died following treatment with the recently approved gene therapy ... The patient died after experiencing acute liver ...

Shares of Sarepta, based in Cambridge, Massachusetts, dropped more than 27% on Tuesday, closing at about $73 per share. Elevidys, which costs $3.2 million for a one-time infusion, was the first gene ...

A few weeks after Sarepta Therapeutics confirmed a patient died after receiving its drug Elevidys, research published April 3 ...

The patient, a young man, suffered acute liver failure after receiving the therapy ... death. Fatalities have also been reported following the launch of Novartis’s Zolgensma, an AAV-delivered ...

Sarepta Therapeutics said on Tuesday that a 16-year-old boy died from acute liver failure months after receiving the company's U.S-approved gene therapy for a rare muscular dystrophy. The patient ...

Sarepta reported a patient death from acute liver failure after Elevidys treatment ... moxeparvovec-rokl), the only approved gene therapy in patients with Duchenne muscular dystrophy.

A patient has died while receiving Elevidys, a gene therapy for Duchenne muscular dystrophy, marking the first known death linked to the treatment. The company behind the drug, Sarepta ...